{
  "docId": "019de073-ce1e-74cc-9870-b1827d8467a5",
  "docSlug": "ce894072ac0bdbdb4be0c6e520599e56",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 31 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 26,
  "pageCount": 31,
  "prevPage": 25,
  "nextPage": 27,
  "slideType": "key_takeaways",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 25,
  "notes": "The slide uses a combination of scatter plots, bar charts, and a waterfall-style selectivity chart to demonstrate drug efficacy and safety profile.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-ce1e-74cc-9870-b1827d8467a5/26",
  "deckHref": "/decks/019de073-ce1e-74cc-9870-b1827d8467a5",
  "deckJsonHref": "/decks/019de073-ce1e-74cc-9870-b1827d8467a5.json",
  "deckAnchorHref": "/decks/019de073-ce1e-74cc-9870-b1827d8467a5#slide-26",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.35,
        "x": 0.6,
        "y": 0.2
      },
      "kind": "chart",
      "text": "Avoiding TRK inhibition",
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cfb30c0b-da30-492b-b8e3-52b12391a8cd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.2,
        "x": 0.38,
        "y": 0.2
      },
      "kind": "chart",
      "text": "Brain penetrance",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1e686a26-315d-4ab6-9f5b-d13eabec9670",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.3,
        "x": 0.07,
        "y": 0.2
      },
      "kind": "chart",
      "text": "Activity against ALK wild-type and mutants",
      "attrs": null,
      "subkind": "scatter",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2a5c4ff2-c2a0-46e5-985d-c2abb3b5cce7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.7,
        "x": 0.07,
        "y": 0.88
      },
      "kind": "disclaimer",
      "text": "IC50, half-maximal inhibitory concentration; PO, orally; pTRK, BDNF-stimulated TRKB phosphorylation. Head-to-head clinical studies comparing NVL-655 with currently approved or investigational therapies have not been conducted. Above data from preclinical studies.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bd069d79-1e47-4a07-a2fc-1808b4405c01",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.85,
        "x": 0.07,
        "y": 0.05
      },
      "kind": "title",
      "text": "Preclinical | NVL-655 is a Brain Penetrant, ALK-Selective Inhibitor with the Potential to Avoid TRK-Related CNS Adverse Events",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cea8bbc8-e4e6-4a17-aaff-3ec252264bb3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Chart Selection Guide",
      "slug": "chart-selection-guide",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "861177a9-2a41-4b2b-a260-8041180323c3",
      "evidence": "chart/scatter: Activity against ALK wild-type and mutants",
      "confidence": 0.6
    },
    {
      "name": "Chart Selection Guide",
      "slug": "chart-selection-guide",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "e6b592c3-4631-4cb8-82ca-fe9dcabce9a6",
      "evidence": "chart/bar-grouped: Avoiding TRK inhibition",
      "confidence": 0.6
    },
    {
      "name": "Chart Selection Guide",
      "slug": "chart-selection-guide",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "0191297e-1812-4c15-b64d-f936259da331",
      "evidence": "chart/bar-vertical: Brain penetrance",
      "confidence": 0.6
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}